ZA200407944B - Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins - Google Patents
Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins Download PDFInfo
- Publication number
- ZA200407944B ZA200407944B ZA200407944A ZA200407944A ZA200407944B ZA 200407944 B ZA200407944 B ZA 200407944B ZA 200407944 A ZA200407944 A ZA 200407944A ZA 200407944 A ZA200407944 A ZA 200407944A ZA 200407944 B ZA200407944 B ZA 200407944B
- Authority
- ZA
- South Africa
- Prior art keywords
- diethylamino
- ylamino
- pyrimidin
- dimethylcarbamoyloxyphenyl
- propionic acid
- Prior art date
Links
- 108010044426 integrins Proteins 0.000 title claims abstract description 35
- 102000006495 integrins Human genes 0.000 title claims abstract description 35
- 230000001404 mediated effect Effects 0.000 title claims abstract description 23
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 title abstract description 9
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- -1 4-fluorobenzenesulfonyl Chemical group 0.000 claims description 29
- 235000019260 propionic acid Nutrition 0.000 claims description 22
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- UEHGISKTKRLKLO-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2,4-difluorophenyl)sulfonyl-prop-2-ynylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(CC#C)S(=O)(=O)C1=CC=C(F)C=C1F UEHGISKTKRLKLO-UHFFFAOYSA-N 0.000 claims description 2
- QNBPSKYQBURTTK-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2-fluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=CC=C1F QNBPSKYQBURTTK-UHFFFAOYSA-N 0.000 claims description 2
- XGZSKLPECGWKPZ-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3,4-difluorophenyl)sulfonyl-propan-2-ylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(C(C)C)S(=O)(=O)C1=CC=C(F)C(F)=C1 XGZSKLPECGWKPZ-UHFFFAOYSA-N 0.000 claims description 2
- QKAALEADKHAZAF-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3,4-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=C(F)C(F)=C1 QKAALEADKHAZAF-UHFFFAOYSA-N 0.000 claims description 2
- PFFXAHQMJBDKHJ-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3-fluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=CC(F)=C1 PFFXAHQMJBDKHJ-UHFFFAOYSA-N 0.000 claims description 2
- JODSWHRKWYEUDL-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(4-fluorophenyl)sulfonyl-prop-2-ynylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(CC#C)S(=O)(=O)C1=CC=C(F)C=C1 JODSWHRKWYEUDL-UHFFFAOYSA-N 0.000 claims description 2
- PQYHPONWVXTFQW-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(2,4-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(F)C=C1F PQYHPONWVXTFQW-UHFFFAOYSA-N 0.000 claims description 2
- KBVXEABVOVICFP-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(3,4-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(F)C(F)=C1 KBVXEABVOVICFP-UHFFFAOYSA-N 0.000 claims description 2
- KGSLYLUBNSUZQN-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(4-fluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(F)C=C1 KGSLYLUBNSUZQN-UHFFFAOYSA-N 0.000 claims description 2
- BMCDGJILQKTGDV-UHFFFAOYSA-N 2-[[5-[(3,4-dichlorophenyl)sulfonylmethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 BMCDGJILQKTGDV-UHFFFAOYSA-N 0.000 claims description 2
- MAZNQIVGHXAJRX-UHFFFAOYSA-N 2-[[5-[2-(3,5-dichlorophenyl)sulfonylethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 MAZNQIVGHXAJRX-UHFFFAOYSA-N 0.000 claims description 2
- QBKUKQMAGFTCQA-UHFFFAOYSA-N 2-[[5-[2-(4-chlorophenyl)sulfonylethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(Cl)C=C1 QBKUKQMAGFTCQA-UHFFFAOYSA-N 0.000 claims description 2
- IKXAHYJACJXEFL-UHFFFAOYSA-N 2-[[5-[butyl-(4-fluorophenyl)sulfonylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CCCC)C1=CN=C(N(CC)CC)N=C1NC(C(O)=O)CC1=CC=C(OC(=O)N(C)C)C=C1 IKXAHYJACJXEFL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- YQPPFPAOQXSSBY-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2,4-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=C(F)C=C1F YQPPFPAOQXSSBY-UHFFFAOYSA-N 0.000 claims 1
- NADHCGMMZGXNJU-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3,5-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC(F)=CC(F)=C1 NADHCGMMZGXNJU-UHFFFAOYSA-N 0.000 claims 1
- RAPVDKCWUQBKGG-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(C(C)C)S(=O)(=O)C1=CC=C(F)C=C1 RAPVDKCWUQBKGG-UHFFFAOYSA-N 0.000 claims 1
- FQXLXEDBFFIHNX-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(3,5-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC(F)=CC(F)=C1 FQXLXEDBFFIHNX-UHFFFAOYSA-N 0.000 claims 1
- XCPNGIQSOZEOOZ-UHFFFAOYSA-N 2-[[5-(benzenesulfonylmethylamino)-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=CC=C1 XCPNGIQSOZEOOZ-UHFFFAOYSA-N 0.000 claims 1
- FPIRQHBDFYJJDM-UHFFFAOYSA-N 2-[[5-[(3,5-dichlorophenyl)sulfonylmethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 FPIRQHBDFYJJDM-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract description 16
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 208000030507 AIDS Diseases 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 4
- 206010012289 Dementia Diseases 0.000 abstract description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 4
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 230000009401 metastasis Effects 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 abstract description 4
- 208000014644 Brain disease Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 45
- 239000004480 active ingredient Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000008107 starch Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000010062 adhesion mechanism Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- IKHARSQFGRMOKN-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2,6-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=C(F)C=CC=C1F IKHARSQFGRMOKN-UHFFFAOYSA-N 0.000 description 1
- AIGZEIASVOBQCI-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(2,3-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=CC(F)=C1F AIGZEIASVOBQCI-UHFFFAOYSA-N 0.000 description 1
- BBTTXCPSXDESDD-UHFFFAOYSA-N 2-[[5-[(4-chlorophenyl)sulfonyl-propan-2-ylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(C(C)C)S(=O)(=O)C1=CC=C(Cl)C=C1 BBTTXCPSXDESDD-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010002921 Aortitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38324402P | 2002-05-24 | 2002-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200407944B true ZA200407944B (en) | 2006-07-26 |
Family
ID=29584533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200407944A ZA200407944B (en) | 2002-05-24 | 2004-10-01 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins |
Country Status (17)
Country | Link |
---|---|
US (2) | US7335663B2 (fr) |
EP (1) | EP1507533B1 (fr) |
JP (1) | JP4413135B2 (fr) |
CN (1) | CN1311829C (fr) |
AT (1) | ATE464298T1 (fr) |
AU (1) | AU2003237302B8 (fr) |
BR (1) | BR0309619A (fr) |
CA (1) | CA2480756A1 (fr) |
DE (1) | DE60332109D1 (fr) |
EA (1) | EA008180B1 (fr) |
IL (1) | IL164323A (fr) |
MX (1) | MXPA04011657A (fr) |
NO (1) | NO20045276L (fr) |
NZ (1) | NZ535723A (fr) |
TW (1) | TW200307671A (fr) |
WO (1) | WO2003099231A2 (fr) |
ZA (1) | ZA200407944B (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2339738T3 (es) * | 1999-01-22 | 2010-05-25 | Elan Pharmaceuticals, Inc. | Derivados de acilo los cuales tratan trastornos relacionados con vla-4. |
CA2528723A1 (fr) * | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methodes et compositions de traitement de la polyarthrite rhumatoide |
JP2007528397A (ja) * | 2004-03-10 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Vla−4アンタゴニスト |
NZ588839A (en) * | 2004-07-08 | 2012-09-28 | Elan Pharm Inc | Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
BRPI0514415A (pt) * | 2004-08-16 | 2008-06-10 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
CA2851103A1 (fr) * | 2005-09-29 | 2007-04-12 | Elan Pharmaceuticals, Inc. | Composes de pyrimidinyl amide qui inhibent l'adherence leucocytaire a mediation par vla-4 |
NZ567270A (en) * | 2005-09-29 | 2011-06-30 | Elan Pharm Inc | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
KR20080100271A (ko) * | 2006-02-27 | 2008-11-14 | 엘란 파마슈티칼스, 인크. | Vla-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물 |
US20070207141A1 (en) * | 2006-02-28 | 2007-09-06 | Ivan Lieberburg | Methods of treating inflammatory and autoimmune diseases with natalizumab |
CA2641160A1 (fr) * | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methodes pour traiter des maladies inflammatoires et auto-immunes avec des composes inhibiteurs alpha-4 |
JP5504390B2 (ja) | 2006-03-03 | 2014-05-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法 |
EP2231185A4 (fr) * | 2007-12-07 | 2012-06-27 | Elan Pharm Inc | Procédés et compositions pour traiter des tumeurs liquides |
EP2424841A1 (fr) * | 2009-04-27 | 2012-03-07 | Elan Pharmaceuticals Inc. | Antagonistes à base de pyridinone d'intégrines alpha-4 |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
PL2524060T3 (pl) | 2010-01-11 | 2018-05-30 | Biogen Ma Inc. | Test wykrywający przeciwciała przeciwko wirusowi jc |
US8343706B2 (en) | 2010-01-25 | 2013-01-01 | International Business Machines Corporation | Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same |
EP3004334A4 (fr) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | Méthodes d'évaluation de risque de développement d'une lemp |
EP3810085A1 (fr) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine |
CA3114240C (fr) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7 |
WO2020092401A1 (fr) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOSÉS POUR INHIBITION DE L'INTÉGRINE ALPHA 4β7 |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
EP3873884A1 (fr) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7 |
CN111197057B (zh) * | 2018-11-19 | 2024-04-19 | 中国科学院分子细胞科学卓越创新中心 | 调控免疫细胞迁移的组合物和方法 |
JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ, インコーポレイテッド | α4β7インテグリンの阻害のための化合物 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2525656A1 (de) | 1974-06-19 | 1976-01-15 | Sandoz Ag | Verfahren zur herstellung neuer heterocyclischer verbindungen |
US4073914A (en) | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4041156A (en) | 1974-11-08 | 1977-08-09 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4018915A (en) | 1976-01-05 | 1977-04-19 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4046876A (en) | 1974-11-08 | 1977-09-06 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4070457A (en) * | 1974-11-08 | 1978-01-24 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4104392A (en) * | 1974-11-08 | 1978-08-01 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them |
US4055651A (en) | 1974-11-08 | 1977-10-25 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4096255A (en) * | 1974-11-08 | 1978-06-20 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods |
US4055636A (en) * | 1974-11-08 | 1977-10-25 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
JPS5727454B2 (fr) * | 1975-02-21 | 1982-06-10 | ||
CA1102316A (fr) | 1975-12-09 | 1981-06-02 | Shosuke Okamoto | Traduction non-disponible |
US4018913A (en) | 1976-01-14 | 1977-04-19 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4036955A (en) * | 1976-07-22 | 1977-07-19 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
DE2742173A1 (de) * | 1977-09-20 | 1979-03-29 | Bayer Ag | Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
IT1211096B (it) | 1981-08-20 | 1989-09-29 | Lpb Ist Farm | Pirimidine e s.triazinici adattivita' ipolipidemizzante. |
US4672065A (en) | 1982-11-19 | 1987-06-09 | Chevron Research Company | N-substituted phenoxyacetamide fungicides |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4565814A (en) | 1983-01-28 | 1986-01-21 | Sanofi | Pyridazine derivatives having a psychotropic action and compositions |
JPS59212480A (ja) | 1983-05-17 | 1984-12-01 | Nippon Soda Co Ltd | ピリダジン誘導体及び除草剤 |
DE3322720A1 (de) * | 1983-06-24 | 1985-01-03 | Chemische Werke Hüls AG, 4370 Marl | Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer |
US4505910A (en) * | 1983-06-30 | 1985-03-19 | American Home Products Corporation | Amino-pyrimidine derivatives, compositions and use |
NZ210669A (en) | 1983-12-27 | 1988-05-30 | Syntex Inc | Benzoxazin-4-one derivatives and pharmaceutical compositions |
PH22520A (en) | 1984-11-12 | 1988-10-17 | Yamanouchi Pharma Co Ltd | Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them |
US4959364A (en) * | 1985-02-04 | 1990-09-25 | G. D. Searle & Co. | Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JPH0784424B2 (ja) | 1987-04-15 | 1995-09-13 | 味の素株式会社 | チロシン誘導体及びその用途 |
EP0330506A3 (fr) * | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Protéines VLA |
DE3904931A1 (de) * | 1989-02-17 | 1990-08-23 | Bayer Ag | Pyridyl-substituierte acrylsaeureester |
US5030644A (en) * | 1989-07-31 | 1991-07-09 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
US4992439A (en) | 1990-02-13 | 1991-02-12 | Bristol-Myers Squibb Company | Pyridazine carboxylic acids and esters |
FR2679903B1 (fr) | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
DE4108029A1 (de) | 1991-03-13 | 1992-09-17 | Bayer Ag | Triazinyl-substituierte acrylsaeureester |
AU1354292A (en) | 1991-03-18 | 1992-10-21 | Pentapharm Ag | Parasubstituted phenylalanine derivates |
IT1247509B (it) | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
US5296486A (en) | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
AU3420693A (en) | 1991-12-24 | 1993-07-28 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
NZ249789A (en) * | 1992-03-11 | 1997-07-27 | Narhex Ltd | Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions |
DE4227748A1 (de) | 1992-08-21 | 1994-02-24 | Bayer Ag | Pyridyloxy-acrylsäureester |
JP2848232B2 (ja) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
JPH10506608A (ja) | 1994-07-11 | 1998-06-30 | アセナ ニューロサイエンシーズ,インコーポレイテッド | 白血球接着のインヒビター |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
AU702487B2 (en) * | 1995-08-30 | 1999-02-25 | G.D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
CZ288178B6 (en) | 1995-09-29 | 2001-05-16 | Sankyo Co | Milbemycin-5-oxime derivatives substituted in position 13-, and their use |
DE19536891A1 (de) | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
DE19548709A1 (de) | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
PT910575E (pt) | 1996-06-21 | 2003-02-28 | Takeda Chemical Industries Ltd | Lipossomas fusogenicos |
JP2000516575A (ja) | 1996-06-28 | 2000-12-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | インテグリンインヒビターとしてのフェニルアラニン誘導体 |
DE19629817A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647317A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Schering Agrevo Gmbh | Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
HUP0000492A3 (en) | 1996-11-22 | 2000-06-28 | Lilly Co Eli | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
WO1998033783A1 (fr) | 1997-02-04 | 1998-08-06 | Versicor, Inc. | Syntheses de banques combinatoires et de phases solides de 3,1-benzoxazine-4-ones |
DE19713000A1 (de) | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
DE69833654T2 (de) | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
CA2291778A1 (fr) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire |
KR20010022406A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Vla-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물 |
AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
CN1133648C (zh) | 1997-07-31 | 2004-01-07 | 伊兰药品公司 | 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物 |
AU8678698A (en) | 1997-07-31 | 1999-02-22 | American Home Products Corporation | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
HU229362B1 (en) | 1997-08-22 | 2013-11-28 | Hoffmann La Roche | N-alkanoylphenylalanine derivatives |
ES2214728T3 (es) | 1997-08-22 | 2004-09-16 | F. Hoffmann-La Roche Ag | Derivados de n-aroilfenilalanina. |
JP4564654B2 (ja) | 1998-01-23 | 2010-10-20 | ノバルティス アーゲー | Vla−4アンタゴニスト |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
CZ20003672A3 (cs) | 1998-04-10 | 2001-08-15 | G. D. Searle & Co. | Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu |
JP4753403B2 (ja) | 1998-04-16 | 2011-08-24 | エンサイシブ・フアーマシユーテイカルズ,インコーポレイテツド | インテグリンのそのレセプターへの結合を阻害する化合物 |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
WO2000043369A1 (fr) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4 |
ES2339738T3 (es) * | 1999-01-22 | 2010-05-25 | Elan Pharmaceuticals, Inc. | Derivados de acilo los cuales tratan trastornos relacionados con vla-4. |
-
2003
- 2003-05-26 TW TW092114184A patent/TW200307671A/zh unknown
- 2003-05-27 CA CA002480756A patent/CA2480756A1/fr not_active Abandoned
- 2003-05-27 US US10/494,788 patent/US7335663B2/en not_active Expired - Fee Related
- 2003-05-27 DE DE60332109T patent/DE60332109D1/de not_active Expired - Lifetime
- 2003-05-27 EP EP03736768A patent/EP1507533B1/fr not_active Expired - Lifetime
- 2003-05-27 AU AU2003237302A patent/AU2003237302B8/en not_active Ceased
- 2003-05-27 JP JP2004506758A patent/JP4413135B2/ja not_active Expired - Fee Related
- 2003-05-27 BR BR0309619-0A patent/BR0309619A/pt not_active IP Right Cessation
- 2003-05-27 AT AT03736768T patent/ATE464298T1/de not_active IP Right Cessation
- 2003-05-27 US US10/447,208 patent/US7008949B2/en not_active Expired - Fee Related
- 2003-05-27 CN CNB038112582A patent/CN1311829C/zh not_active Expired - Fee Related
- 2003-05-27 EA EA200401561A patent/EA008180B1/ru not_active IP Right Cessation
- 2003-05-27 MX MXPA04011657A patent/MXPA04011657A/es active IP Right Grant
- 2003-05-27 WO PCT/US2003/017150 patent/WO2003099231A2/fr active IP Right Grant
- 2003-05-27 NZ NZ535723A patent/NZ535723A/en unknown
-
2004
- 2004-09-28 IL IL164323A patent/IL164323A/en not_active IP Right Cessation
- 2004-10-01 ZA ZA200407944A patent/ZA200407944B/en unknown
- 2004-12-01 NO NO20045276A patent/NO20045276L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA008180B1 (ru) | 2007-04-27 |
CA2480756A1 (fr) | 2003-12-04 |
NO20045276L (no) | 2004-12-01 |
DE60332109D1 (de) | 2010-05-27 |
WO2003099231A3 (fr) | 2004-01-22 |
AU2003237302A1 (en) | 2003-12-12 |
TW200307671A (en) | 2003-12-16 |
CN1652789A (zh) | 2005-08-10 |
NZ535723A (en) | 2005-08-26 |
EA200401561A1 (ru) | 2005-06-30 |
EP1507533A4 (fr) | 2007-05-23 |
EP1507533B1 (fr) | 2010-04-14 |
AU2003237302B2 (en) | 2008-03-06 |
US20050130999A1 (en) | 2005-06-16 |
US7008949B2 (en) | 2006-03-07 |
MXPA04011657A (es) | 2005-08-18 |
BR0309619A (pt) | 2005-06-28 |
US20040142954A1 (en) | 2004-07-22 |
ATE464298T1 (de) | 2010-04-15 |
AU2003237302B8 (en) | 2008-04-03 |
IL164323A (en) | 2010-02-17 |
WO2003099231A2 (fr) | 2003-12-04 |
EP1507533A2 (fr) | 2005-02-23 |
CN1311829C (zh) | 2007-04-25 |
US7335663B2 (en) | 2008-02-26 |
JP4413135B2 (ja) | 2010-02-10 |
IL164323A0 (en) | 2005-12-18 |
JP2005529155A (ja) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200407944B (en) | Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins | |
ZA200407590B (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 intergrins | |
JP3087763B2 (ja) | 新規な複素環式化合物およびそれを含有する医薬組成物 | |
DE69637040T2 (de) | Derivate monocyclischer Polyamine, ihre Herstellung und ihre Verwendung als antivirale Mittel | |
DE69629156T2 (de) | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel | |
WO2009017838A2 (fr) | Combinaisons d'inhibiteurs jak-2 et d'autres agents | |
CA2568832A1 (fr) | Derives d'indole en tant qu'agents antiviraux | |
CN103347866A (zh) | 作为治疗呼吸控制不适或疾病的呼吸兴奋剂的新化合物 | |
FI120403B (fi) | 4-(2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena | |
WO2017202311A1 (fr) | Forme polycristalline de 2-aminopyrimidine | |
US12012386B2 (en) | Olaparib oxalic acid cocrystals and their pharmaceutical use | |
JPH0532635A (ja) | ヒスタミン誘導体の治療への応用と、新規なヒスタミン誘導体と、この誘導体の医薬としての使用 | |
JPS62919B2 (fr) | ||
WO2023083139A1 (fr) | Complexe à charge équilibrée, son procédé de préparation et son utilisation | |
WO2015109925A1 (fr) | Forme cristalline de médicament contre l'hépatite c et son procédé de préparation, sa composition pharmaceutique et son utilisation | |
JPS6223723B2 (fr) | ||
JPH01139572A (ja) | ピリミジン類及びその薬学的に許容される塩類 | |
JPS61205257A (ja) | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 | |
WO2023084313A2 (fr) | Co-cristaux de benzamide thérapeutiques | |
JPS58174322A (ja) | 線溶促進剤 | |
EP0171942A1 (fr) | Composition antitumorale | |
JPS6231689B2 (fr) |